Susanna High
2020
In 2020, Susanna High earned a total compensation of $3.7M as Chief Operating Officer at Dyne Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $73,336 |
|---|---|
| Option Awards | $2,646,267 |
| Salary | $167,778 |
| Stock Awards | $858,106 |
| Other | $418 |
| Total | $3,745,905 |
High received $2.6M in option awards, accounting for 71% of the total pay in 2020.
High also received $73.3K in non-equity incentive plan, $167.8K in salary, $858.1K in stock awards and $418 in other compensation.
Rankings
In 2020, Susanna High's compensation ranked 3,085th out of 13,090 executives tracked by ExecPay. In other words, High earned more than 76.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,085 out of 13,090 | 76th |
Division Manufacturing | 1,202 out of 5,618 | 79th |
Major group Chemicals And Allied Products | 458 out of 2,251 | 80th |
Industry group Drugs | 396 out of 1,951 | 80th |
Industry Pharmaceutical Preparations | 295 out of 1,456 | 80th |
Source: SEC filing on April 14, 2021.
High's colleagues
We found two more compensation records of executives who worked with Susanna High at Dyne Therapeutics in 2020.
News
Dyne Therapeutics CEO Josh Brumm's 2023 pay jumps 38% to $6M
April 5, 2024
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021